2026-01-02 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the data provided.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Johnson & Johnson is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **Return Rate Comparison:** JNJ's cumulative return of 52.50% significantly underperforms the S&P 500 (VOO) return of 105.07%. The divergence is -52.57%.
*   **Divergence Context:** The divergence of -52.6 puts it at 27.1% relative to its historical fluctuation range (Max:7.1, Min:-74.8).
*   **Alpha/Beta Analysis Table:**

    | Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
    |------------|------|------|-------|------|-------|
    | 2016-2018  | 24.0% | 10.1% | -6.0% | 0.7 | 310.9 |
    | 2017-2019  | 29.0% | 71.1% | -13.0% | 0.7 | 351.4 |
    | 2018-2020  | 14.0% | 80.3% | -19.0% | 0.7 | 379.2 |
    | 2019-2021  | 29.0% | 80.3% | -47.0% | 0.6 | 412.2 |
    | 2020-2022  | 19.0% | 80.3% | 0.0% | 0.5 | 425.6 |
    | 2021-2023  | -4.0% | 79.5% | -32.0% | 0.3 | 377.6 |
    | 2022-2024  | -16.0% | 79.5% | -46.0% | 0.2 | 348.4 |
    | 2023-2025  | 27.0% | 79.6% | -41.0% | 0.1 | 498.6 |

*   **Alpha/Beta Analysis:**  JNJ has consistently underperformed the market (negative Alpha) across these periods. The Beta is decreasing over time, indicating that JNJ is becoming less correlated with the market. The high MDD(Maximum Drawdown) values suggest potentially high risk and volatility. The CAGR has been volatile over the years. Market Cap has been steadily increasing except for the period between 2021 and 2024.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** $206.95
*   **Last Market Change:** Small increase of $0.02 from the previous close.
*   **Moving Averages:**
    *   5-day SMA: 207.37
    *   20-day SMA: 206.89
    *   60-day SMA: 198.45

*   **Analysis:** The 5-day SMA is slightly above the 20-day SMA, which is also slightly above the current price, suggesting a potential short-term downtrend. The 60-day SMA is significantly lower than the other two, indicating a longer-term uptrend.

**3) Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommended)
*   **RSI:** 50.90 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.35 (Slightly bearish momentum)
*   **Hybrid Signal:** "cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.70)" indicates a buy recommendation with caution due to the moderate market risk.
*   **Recent Divergence Change:** 3.2 (+) "단기상승" indicates a short-term upward trend.
*   **Expected Return:** 0.0%. The expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point is 0%.

**4) Recent News & Significant Events**

*   **Key Headlines (Summarized):**
    *   **Positive Outlook:** Forbes asks if there's more upside for JNJ in 2026.
    *   **Cash Flow Justification:** Yahoo Finance questions if J&J's 2025 surge is justified by its financials.
    *   **Acquisition:** JNJ closes a $3.05B Halda cancer deal; Barclays lifts target.
    *   **Institutional Investment:** Ethic Inc. purchases JNJ shares, and other institutional investors are raising their stakes.
    *   **Future Expectations:** Trefis discusses what to expect from JNJ stock.

*   **Analysis:** The news is a mixed bag. There is some optimism about future potential, but also scrutiny of recent performance and acquisitions. The institutional investment is a positive signal.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean rating of 2.16)
*   **Target Price:** Average target of $210.13, with a high of $240 and a low of $155.
*   **Recent Rating Changes:** No information is provided about recent rating changes.

*   **Analysis:** Analysts, on average, have a positive outlook on JNJ with a consensus buy rating. The average target price suggests a potential upside from the current price.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|----------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-10-22 | 1.12 | 22.47 B$ |

*Note: There is a duplicated row in the original table. I have included it as is.*

*   **Analysis:** EPS and revenue have been fluctuating. The most recent quarter (2025-10-22) showed a reasonable EPS and the highest revenue in the given period. The duplication of data for 2025-10-22 and 2024-10-23 with same value makes the analysis difficult.

**6) Financial Information**

Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

*   **Analysis: Revenue and Profitability**: Revenue is trending upwards. JNJ is maintaining a healthy profit margin close to 70%.

*   **Analysis: Capital and Profitability**: JNJ has increasing Equity. ROE is quite volatile, with a high in 2025-03-31 and much lower values in other quarters.

**7) Comprehensive Analysis (Summary)**

*   **Performance:** JNJ has significantly underperformed the S&P 500 in terms of cumulative return. Its Alpha values confirm this underperformance. The beta is falling, indicating that JNJ is becoming less correlated with the market.
*   **Technicals:** The stock is currently trading near its 20-day SMA and above its 60-day SMA, suggesting some short-term weakness but long-term strength. The RSI is neutral. The MRI shows medium investment recommended.
*   **News:** Recent news is mixed, with some positive outlooks balanced by scrutiny of financials and acquisitions.
*   **Analysts:** Analysts have a generally positive view (buy rating) and see some potential upside.
*   **Financials:** The revenue is growing and the company is maintaining high profit margins.
*   **Overall:** JNJ appears to be a fundamentally sound company with growing revenue and strong profitability. However, it has underperformed the market recently.

**Conclusion:**

Based on the data, JNJ could be considered a cautious buy. While it has underperformed the market, analysts are generally positive, and the company has solid financials. The MRI and Hybrid Signal provide moderate investment recommendations. Investors should consider the negative Alpha and the potential for continued underperformance relative to the S&P 500. It's also important to note the moderate fluctuation in the RSI, which suggests a certain level of volatility. The short-term uptrend in the recent divergence change and the strong profit margins might be appealing to some investors.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.